181 related articles for article (PubMed ID: 29193561)
1. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
Loughlin AM; Qiao Q; Nunes AP; Öhman P; Ezzy S; Yochum L; Clifford CR; Gately R; Dore DD; Seeger JD
Diabetes Obes Metab; 2018 Apr; 20(4):898-909. PubMed ID: 29193561
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States.
Loughlin AM; Qiao Q; Nunes AP; Ezzy SM; Yochum L; Clifford CR; Gately RV; Dore DD; Seeger JD
Diabetes Spectr; 2018 May; 31(2):129-137. PubMed ID: 29773932
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care.
Nunes AP; Loughlin AM; Qiao Q; Ezzy SM; Yochum L; Clifford CR; Gately RV; Dore DD; Seeger JD
Diabetes Ther; 2017 Dec; 8(6):1349-1364. PubMed ID: 28983857
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
[TBL] [Abstract][Full Text] [Related]
5. All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine.
Wittbrodt E; Kong AM; Moore-Schiltz L; Juneau P
Diabetes Obes Metab; 2018 Mar; 20(3):672-680. PubMed ID: 29083520
[TBL] [Abstract][Full Text] [Related]
6. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Grimm M; Li Y; Brunell SC; Blase E
Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
[TBL] [Abstract][Full Text] [Related]
7. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
[TBL] [Abstract][Full Text] [Related]
9. Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study.
Morgan CL; Qiao Q; Grandy S; Johnsson K; Jenkins-Jones S; Holden S; Currie CJ
Diabetes Ther; 2018 Feb; 9(1):269-283. PubMed ID: 29318537
[TBL] [Abstract][Full Text] [Related]
10. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Malloy J; Meloni A; Han J
Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
[TBL] [Abstract][Full Text] [Related]
12. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
[TBL] [Abstract][Full Text] [Related]
13. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
Diamant M; Van Gaal L; Stranks S; Guerci B; MacConell L; Haber H; Scism-Bacon J; Trautmann M
Diabetes Care; 2012 Apr; 35(4):683-9. PubMed ID: 22357185
[TBL] [Abstract][Full Text] [Related]
15. Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
Wang X; Zhang H; Zhang Q; Guan M; Sheng S; Mo W; Zou M; Li J; Bi J; Tang X; Zeng H; He J; Xu G; Li P; Xue Y
Am J Nephrol; 2020; 51(10):806-814. PubMed ID: 32966971
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.
Peskin BR; Shcheprov AV; Boye KS; Bruce S; Maggs DG; Gaebler JA
Diabetes Obes Metab; 2011 Oct; 13(10):921-7. PubMed ID: 21624032
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
Guja C; Frías JP; Suchower L; Hardy E; Marr G; Sjöström CD; Jabbour SA
Diabetes Ther; 2020 Jul; 11(7):1467-1480. PubMed ID: 32306296
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
[TBL] [Abstract][Full Text] [Related]
20. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
